Document 0040
 DOCN  M9650040
 TI    [Therapy and prognosis of tuberculosis]
 DT    9605
 AU    Fischer B; Ferlinz R; III Medizinischen Klinik und Poliklinik, Univ.
       Mainz.
 SO    Versicherungsmedizin. 1995 Dec 1;47(6):212-6. Unique Identifier :
       AIDSLINE MED/96119093
 AB    Treatment and prognosis of tuberculosis. Worldwide the so-called
       short-course chemotherapy has become the standard treatment for
       tuberculosis. The 6-month regimen consists of isoniazid, rifampin, and
       pyrazinamid given for 2 month followed by isoniazid and rifampin for 4
       month. Ethambutol or streptomycin is added in the first 2 month in
       patients with advanced disease. This recommendation applies to both
       HIV-infected and uninfected persons. The major determinant of the
       outcome of treatment is patient adherence to the drug regimen. In
       susceptible strains the success rate with the 6-month regimen in sputum
       conversion is far beyond 90% within the first two month of therapy. The
       relapse rate after 3 to 5 years is about 0-3%. Multiple-drug-resistant
       tuberculosis (i.e., resistance to at least two drugs) presents difficult
       treatment problems. Treatment must be individualized and based on
       susceptibility studies. For patients with tuberculosis that is resistant
       to rifampin and isoniazid, even the best available treatment is often
       unsuccessful. The role of new agents such as the quinolone derivatives
       and amikacin in the treatment of multidrug-resistant disease is not
       known, although these drugs are commonly being used in such cases.
 DE    Adult  Antitubercular Agents/ADVERSE EFFECTS/*THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/DRUG THERAPY  Dose-Response
       Relationship, Drug  Drug Administration Schedule  Drug Therapy,
       Combination  English Abstract  Human  Tuberculosis/*DRUG THERAPY
       Tuberculosis, Multidrug-Resistant/DRUG THERAPY  Tuberculosis,
       Pulmonary/*DRUG THERAPY  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).